Literature DB >> 28209634

Cognitive decline in prostate cancer patients undergoing ADT: a potential role for exercise training.

Niamh L Mundell1, Robin M Daly2, Helen Macpherson2, Steve F Fraser2.   

Abstract

Androgen deprivation therapy (ADT) is an effective and widely prescribed treatment for prostate cancer (PCa), but it is associated with multiple treatment-induced adverse effects that impact on various musculoskeletal and cardiometabolic health outcomes. Emerging research has shown that ADT is also associated with cognitive impairment, which has been linked to a loss of independence, increased falls and fracture risk and greater use of medical services. The aim of this review is to outline the evidence related to the effect of ADT use on cognitive function, and propose a role for exercise training as part of usual care to prevent and/or manage cognitive impairments for PCa survivors on ADT. The following results have been obtained from this study. ADT has been shown to adversely affect specific cognitive domains, particularly verbal memory, visuomotor function, attention and executive function. However, current clinical guidelines do not recommend routine assessment of cognitive function in these men. No studies have examined whether exercise training can preserve or improve cognitive function in these men, but in healthy adults', multimodal exercise training incorporating aerobic training, progressive resistance training (PRT) and challenging motor control exercises have the potential to attenuate cognitive decline. In conclusion, as treatment with ADT for men with PCa has been associated with a decline in cognition, it is recommended that cognitive function be routinely monitored in these men and that regular exercise training be prescribed to preserve (or improve) cognitive function. Assessment of cognition and individualised exercise training should be considered in the usual treatment plan of PCa patients receiving ADT.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  androgen deprivation therapy; cognitive function; exercise; prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28209634     DOI: 10.1530/ERC-16-0493

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  11 in total

1.  Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial.

Authors:  Niamh Liana Mundell; Patrick J Owen; Jack Dalla Via; Helen Macpherson; Robin Daly; Patricia M Livingston; Timo Rantalainen; Stephen Foulkes; Jerremy Millar; Declan G Murphy; Steve Fraser
Journal:  BMJ Open       Date:  2022-06-24       Impact factor: 3.006

2.  Improve cognitive impairment using mefenamic acid non-steroidal anti-inflammatory therapy: additional beneficial effect found in a controlled clinical trial for prostate cancer therapy.

Authors:  Valery Melnikov; Daniel Tiburcio-Jimenez; Martha A Mendoza-Hernandez; Josuel Delgado-Enciso; Luis De-Leon-Zaragoza; Jose Guzman-Esquivel; Iram P Rodriguez-Sanchez; Margarita L Martinez-Fierro; Agustin Lara-Esqueda; Osiris G Delgado-Enciso; Ivan Jacinto-Cortes; Sergio A Zaizar-Fregoso; Brenda A Paz-Michel; Efren Murillo-Zamora; Ivan Delgado-Enciso; Hector R Galvan-Salazar
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

Review 3.  Effects of exercise interventions on social and cognitive functioning of men with prostate cancer: a meta-analysis.

Authors:  Yuan-Yuan Fang; Yun-Hsiang Lee; Jui-Chun Chan; Piao-Yi Chiou; Xiao-Yin Chou; Wen-Tzu Chiu; Chia-Tai Hung
Journal:  Support Care Cancer       Date:  2020-01-07       Impact factor: 3.603

Review 4.  Cognitive and Psychological Impacts of Different Treatment Options for Prostate Cancer: A Critical Analysis.

Authors:  Konstantina G Yiannopoulou; Aikaterini I Anastasiou; Konstantinos Kontoangelos; Charalambos Papageorgiou; Ioannis P Anastasiou
Journal:  Curr Urol       Date:  2020-12-18

5.  No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study.

Authors:  Jui-Ming Liu; Chien-Yu Lin; Heng-Chang Chuang; Ren-Jun Hsu
Journal:  Ther Clin Risk Manag       Date:  2018-09-28       Impact factor: 2.423

6.  Cognitive function, depression, and anxiety in patients undergoing radical prostatectomy with and without adjuvant treatment.

Authors:  Piotr Jarzemski; Bartosz Brzoszczyk; Alicja Popiołek; Agnieszka Stachowicz-Karpińska; Szymon Gołota; Maciej Bieliński; Alina Borkowska
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-05       Impact factor: 2.570

7.  Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.

Authors:  Patrick J Owen; Robin M Daly; Patricia M Livingston; Niamh L Mundell; Jack Dalla Via; Jeremy L Millar; Steve F Fraser
Journal:  Trials       Date:  2017-10-03       Impact factor: 2.279

Review 8.  Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review.

Authors:  Barbara Bressi; Maribel Cagliari; Massimiliano Contesini; Elisa Mazzini; Franco Antonio Mario Bergamaschi; Alfredo Moscato; Maria Chiara Bassi; Stefania Costi
Journal:  Support Care Cancer       Date:  2020-10-29       Impact factor: 3.603

Review 9.  Roles and molecular mechanisms of physical exercise in cancer prevention and treatment.

Authors:  Qiaoyun Wang; Wenli Zhou
Journal:  J Sport Health Sci       Date:  2020-07-30       Impact factor: 7.179

10.  Analysis of Brain Functions in Men with Prostate Cancer under Androgen Deprivation Therapy: A One-Year Longitudinal Study.

Authors:  Vanessa Sánchez-Martínez; Cristina Buigues; Rut Navarro-Martínez; Laura García-Villodre; Noura Jeghalef; María Serrano-Carrascosa; José Rubio-Briones; Omar Cauli
Journal:  Life (Basel)       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.